Table 1 Clinical and laboratory characteristics of the study subjects
Variable | Frequency (%) |
|---|---|
BMI, mean (SD), kg/m2 | 26.7 (4.6) |
 Categories, n (%) | |
  Underweight (<18.5) | 6 (1.6) |
  Normal (18.5–25) | 139 (36.1) |
  Overweight (25–29.9) | 154 (40.0) |
  Obese (≥30) | 86 (22.3) |
 Blood Pressure (BP) mmHg | |
  Hypertensive, BP > 140/90 mmHg or on treatment | 191 (49.6) |
  Normal BP | 194 (50.4) |
 Hypertension treatment, Users, | |
  ACEi’s/ARBs | 132 (69.4) |
  Calcium channel blocker(CCBs) | 120 (63.0) |
  Diuretics(thiazides, Spironolactone, Furosemide) | 90 (47.8) |
 Glucose-lowering treatment | |
  Diet-only | 11 (2.9) |
  Oral Glucose-lowering Agents(OGLAs)-only | 262 (68.1) |
  Insulin-only | 66 (17.1) |
  Combined Oral Glucose-lowering Agents and Insulin | 46 (12.0) |
 Glycemic control | |
  Mean HbA1c, % | 8.3(3.0) |
  Poor (HbA1c > 7%) | 233 (60.5) |
  Good (HbA1c ≤ 7%) | 152 (39.5) |
Total cholesterol, mean (SD), mmol/L | 4.6 (1.2) |
 Categories, n (%) | |
  High ≥4.12 | 88 (22.9) |
  Normal, <4.12 | 297 (77.1) |
HDL, mean (SD), mmol/L | 1.3 (0.9) |
 Categories, n (%) | |
  Low ≤1.00 | 80 (20.8) |
  Normal >1.00 | 305 (79.2) |
Triglycerides, mean (SD), mmol/L | 1.7 (1.0) |
 Categories, n (%) | |
  High, >1.7 | 210 (54.5) |
  Normal ≤1.7 | 175 (45.5) |
LDL, mean (SD), mmol/L | 2.4 (0.9) |
 Categories, n (%) | |
  High, >2.0 | 297 (77.1) |
  Normal ≤2.0 | 88 (22.9) |
 Albuminuria | |
  Albuminuria | 126 (32.7) |
  Normal | 259 (67.3) |